Published in Curr Opin Oncol on January 01, 2014
Targeting amino acid metabolism in cancer growth and anti-tumor immune response. World J Biol Chem (2015) 0.81
Cytosolic DNA sensing via the stimulator of interferon genes adaptor: Yin and Yang of immune responses to DNA. Eur J Immunol (2014) 0.79
Prevention of allogeneic fetal rejection by tryptophan catabolism. Science (1998) 9.80
GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity (2005) 4.53
Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J Clin Invest (2007) 4.44
Autoimmunity initiates in nonhematopoietic cells and progresses via lymphocytes in an interferon-dependent autoimmune disease. Immunity (2012) 3.49
Halofuginone inhibits TH17 cell differentiation by activating the amino acid starvation response. Science (2009) 3.47
Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer. J Immunol (2013) 2.96
Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. Immunity (2013) 2.69
STING manifests self DNA-dependent inflammatory disease. Proc Natl Acad Sci U S A (2012) 2.59
IDO is a nodal pathogenic driver of lung cancer and metastasis development. Cancer Discov (2012) 2.56
Indoleamine 2,3 dioxygenase and metabolic control of immune responses. Trends Immunol (2012) 2.37
Prevention of T cell-driven complement activation and inflammation by tryptophan catabolism during pregnancy. Nat Immunol (2001) 2.23
Infectious tolerance via the consumption of essential amino acids and mTOR signaling. Proc Natl Acad Sci U S A (2009) 2.22
Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase. Proc Natl Acad Sci U S A (2008) 2.18
Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. J Exp Med (2013) 2.13
Pyruvate kinase M2 promotes de novo serine synthesis to sustain mTORC1 activity and cell proliferation. Proc Natl Acad Sci U S A (2012) 2.10
Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion. Cancer Res (2012) 1.98
STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients. J Clin Invest (2013) 1.94
Myeloid-derived suppressor cells in cancer patients: a clinical perspective. J Immunother (2012) 1.87
Fibrocytes represent a novel MDSC subset circulating in patients with metastatic cancer. Blood (2013) 1.85
Reduced cytotoxic function of effector CD8+ T cells is responsible for indoleamine 2,3-dioxygenase-dependent immune suppression. J Immunol (2009) 1.72
Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase. Proc Natl Acad Sci U S A (2012) 1.65
IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival. Clin Cancer Res (2012) 1.55
Blocking IDO activity to enhance anti-tumor immunity. Front Biosci (Elite Ed) (2012) 1.46
Halofuginone and other febrifugine derivatives inhibit prolyl-tRNA synthetase. Nat Chem Biol (2012) 1.46
IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophan. Oncoimmunology (2012) 1.37
CDllc+ cells modulate pulmonary immune responses by production of indoleamine 2,3-dioxygenase. Am J Respir Cell Mol Biol (2003) 1.37
Role of aryl hydrocarbon receptor in cancer. Biochim Biophys Acta (2013) 1.37
Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy. Ann N Y Acad Sci (2013) 1.34
Asparagine synthetase: regulation by cell stress and involvement in tumor biology. Am J Physiol Endocrinol Metab (2013) 1.26
The absence of IDO upregulates type I IFN production, resulting in suppression of viral replication in the retrovirus-infected mouse. J Immunol (2010) 1.26
Metabolic control of the Treg/Th17 axis. Immunol Rev (2013) 1.26
Amino acid catabolism: a pivotal regulator of innate and adaptive immunity. Immunol Rev (2012) 1.16
Natural and induced T regulatory cells in cancer. Front Immunol (2013) 1.15
Cutting edge: DNA sensing via the STING adaptor in myeloid dendritic cells induces potent tolerogenic responses. J Immunol (2013) 1.13
IDO1 metabolites activate β-catenin signaling to promote cancer cell proliferation and colon tumorigenesis in mice. Gastroenterology (2013) 1.12
Antimicrobial and immunoregulatory properties of human tryptophan 2,3-dioxygenase. Eur J Immunol (2009) 1.07
Engineering DNA nanoparticles as immunomodulatory reagents that activate regulatory T cells. J Immunol (2012) 1.06
Tryptophan hydroxylase-1 regulates immune tolerance and inflammation. J Exp Med (2012) 1.06
The kynurenine pathway in brain tumor pathogenesis. Cancer Res (2012) 1.03
Myeloid-derived suppressor cells from tumor-bearing mice impair TGF-β-induced differentiation of CD4+CD25+FoxP3+ Tregs from CD4+CD25-FoxP3- T cells. J Leukoc Biol (2012) 1.00
Indoleamine 2,3-dioxygenase, Tregs and cancer. Curr Med Chem (2011) 1.00
Arginase II expressed in cancer-associated fibroblasts indicates tissue hypoxia and predicts poor outcome in patients with pancreatic cancer. PLoS One (2013) 0.99
Modulation of natural killer cell antitumor activity by the aryl hydrocarbon receptor. Proc Natl Acad Sci U S A (2013) 0.99
The emerging roles of AhR in physiology and immunity. Biochem Pharmacol (2013) 0.98
Iron deprivation in cancer--potential therapeutic implications. Nutrients (2013) 0.98
Retinoic acid promotes the development of Arg1-expressing dendritic cells for the regulation of T-cell differentiation. Eur J Immunol (2013) 0.95
Indoleamine 2,3-dioxygenase-1 (IDO1) enhances survival and invasiveness of endometrial stromal cells via the activation of JNK signaling pathway. Int J Clin Exp Pathol (2013) 0.94
Indoleamine 2,3-dioxygenase activity and clinical outcome following induction chemotherapy and concurrent chemoradiation in Stage III non-small cell lung cancer. Oncoimmunology (2013) 0.94
Anti-leukemic mechanisms of pegylated arginase I in acute lymphoblastic T-cell leukemia. Leukemia (2012) 0.94
AMPK and GCN2-ATF4 signal the repression of mitochondria in colon cancer cells. Biochem J (2012) 0.93
Indoleamine 2,3-dioxygenase activity contributes to local immune suppression in the skin expressing human papillomavirus oncoprotein e7. J Invest Dermatol (2013) 0.92
The endogenous tryptophan metabolite and NAD+ precursor quinolinic acid confers resistance of gliomas to oxidative stress. Cancer Res (2013) 0.92
Anti-tumorigenic effects of Type 1 interferon are subdued by integrated stress responses. Oncogene (2012) 0.92
Amino acid deprivation promotes tumor angiogenesis through the GCN2/ATF4 pathway. Neoplasia (2013) 0.90
Borrelidin, a small molecule nitrile-containing macrolide inhibitor of threonyl-tRNA synthetase, is a potent inducer of apoptosis in acute lymphoblastic leukemia. Invest New Drugs (2011) 0.89
Immunoediting and antigen loss: overcoming the achilles heel of immunotherapy with antigen non-specific therapies. Front Oncol (2013) 0.87
Indoleamine 2,3-dioxygenase activity and expression in patients with chronic lymphocytic leukemia. Clin Lymphoma Myeloma Leuk (2012) 0.87
Tryptophan metabolism in carcinoma of the breast. Lancet (1967) 0.87
New and emerging treatments for estrogen receptor-positive breast cancer: focus on everolimus. Ther Clin Risk Manag (2013) 0.87
Altered tryptophan metabolism as a paradigm for good and bad aspects of immune privilege in chronic inflammatory diseases. Front Immunol (2012) 0.85
Indoleamine 2,3-dioxygenase protects corneal endothelial cells from UV mediated damage. Exp Eye Res (2005) 0.84
The role of indoleamine 2,3-dioxygenase in LP-BPM5 murine retroviral disease progression. Virol J (2013) 0.83
L-glutamine is a key parameter in the immunosuppression phenomenon. Biochem Biophys Res Commun (2012) 0.82
Conversion of 2-deoxyglucose-induced growth inhibition to cell death in normoxic tumor cells. Cancer Chemother Pharmacol (2013) 0.81
Cell-extrinsic effects of the tumor unfolded protein response on myeloid cells and T cells. Ann N Y Acad Sci (2013) 0.81
Adaptation to chronic mTOR inhibition in cancer and in aging. Biochem Soc Trans (2013) 0.81
Prognostic role of indoleamine 2,3-dioxygenase in endometrial carcinoma. Gynecol Oncol (2012) 0.80
Molecular programming of steady-state dendritic cells: impact on autoimmunity and tumor immune surveillance. Ann N Y Acad Sci (2013) 0.79
Tumoral indoleamine 2,3-dioxygenase expression predicts poor outcome in laryngeal squamous cell carcinoma. Virchows Arch (2012) 0.79
Tryptophan metabolism in early and advanced breast cancer and carcinoma of the cervix. Clin Chim Acta (1972) 0.76
Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest (2007) 5.05
GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity (2005) 4.53
Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J Clin Invest (2007) 4.44
Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest (2004) 4.27
Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science (2002) 4.02
Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Cancer Res (2007) 3.44
Reprogrammed foxp3(+) regulatory T cells provide essential help to support cross-presentation and CD8(+) T cell priming in naive mice. Immunity (2010) 3.35
Indoleamine 2,3-dioxygenase controls conversion of Foxp3+ Tregs to TH17-like cells in tumor-draining lymph nodes. Blood (2009) 2.88
IDO activates regulatory T cells and blocks their conversion into Th17-like T cells. J Immunol (2009) 2.83
Ligation of B7-1/B7-2 by human CD4+ T cells triggers indoleamine 2,3-dioxygenase activity in dendritic cells. J Immunol (2004) 2.77
Indoleamine 2,3 dioxygenase and metabolic control of immune responses. Trends Immunol (2012) 2.37
Indoleamine 2,3-dioxygenase expression is restricted to fetal trophoblast giant cells during murine gestation and is maternal genome specific. J Reprod Immunol (2004) 2.30
Infectious tolerance via the consumption of essential amino acids and mTOR signaling. Proc Natl Acad Sci U S A (2009) 2.22
Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase. Proc Natl Acad Sci U S A (2008) 2.18
A minor population of splenic dendritic cells expressing CD19 mediates IDO-dependent T cell suppression via type I IFN signaling following B7 ligation. Int Immunol (2005) 2.18
A critical role for the programmed death ligand 1 in fetomaternal tolerance. J Exp Med (2005) 2.13
Kynurenine is an endothelium-derived relaxing factor produced during inflammation. Nat Med (2010) 2.12
Indoleamine 2,3-dioxygenase is a critical regulator of acute graft-versus-host disease lethality. Blood (2007) 2.12
Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection. Int J Cancer (2002) 2.10
IDO and tolerance to tumors. Trends Mol Med (2004) 2.03
An inherently bifunctional subset of Foxp3+ T helper cells is controlled by the transcription factor eos. Immunity (2013) 1.98
Opposing biological functions of tryptophan catabolizing enzymes during intracellular infection. J Infect Dis (2011) 1.86
Functional expression of indoleamine 2,3-dioxygenase by murine CD8 alpha(+) dendritic cells. Int Immunol (2002) 1.69
The tumor-draining lymph node as an immune-privileged site. Immunol Rev (2006) 1.57
Tryptophan deprivation sensitizes activated T cells to apoptosis prior to cell division. Immunology (2002) 1.57
T cell costimulation molecules CD80/86 inhibit osteoclast differentiation by inducing the IDO/tryptophan pathway. Sci Transl Med (2014) 1.56
Influenza-induced expression of indoleamine 2,3-dioxygenase enhances interleukin-10 production and bacterial outgrowth during secondary pneumococcal pneumonia. J Infect Dis (2005) 1.41
Tolerance to apoptotic cells is regulated by indoleamine 2,3-dioxygenase. Proc Natl Acad Sci U S A (2012) 1.37
Inducing the tryptophan catabolic pathway, indoleamine 2,3-dioxygenase (IDO), for suppression of graft-versus-host disease (GVHD) lethality. Blood (2009) 1.35
Dendritic cells, indoleamine 2,3 dioxygenase and acquired immune privilege. Int Rev Immunol (2010) 1.29
Physiologic control of IDO competence in splenic dendritic cells. J Immunol (2011) 1.29
Cell-autonomous control of interferon type I expression by indoleamine 2,3-dioxygenase in regulatory CD19+ dendritic cells. Eur J Immunol (2007) 1.27
Pattern of recruitment of immunoregulatory antigen-presenting cells in malignant melanoma. Lab Invest (2003) 1.23
Indoleamine 2,3-dioxygenase in lung dendritic cells promotes Th2 responses and allergic inflammation. Proc Natl Acad Sci U S A (2008) 1.22
Leishmania major attenuates host immunity by stimulating local indoleamine 2,3-dioxygenase expression. J Infect Dis (2011) 1.18
Amino acid catabolism: a pivotal regulator of innate and adaptive immunity. Immunol Rev (2012) 1.16
B-lymphoid cells with attributes of dendritic cells regulate T cells via indoleamine 2,3-dioxygenase. Proc Natl Acad Sci U S A (2010) 1.15
Cutting edge: DNA sensing via the STING adaptor in myeloid dendritic cells induces potent tolerogenic responses. J Immunol (2013) 1.13
Targeting the immunoregulatory indoleamine 2,3 dioxygenase pathway in immunotherapy. Immunotherapy (2009) 1.10
Engineering DNA nanoparticles as immunomodulatory reagents that activate regulatory T cells. J Immunol (2012) 1.06
Highlights of 10 years of immunology in Nature Reviews Immunology. Nat Rev Immunol (2011) 1.06
A high-affinity, tryptophan-selective amino acid transport system in human macrophages. J Leukoc Biol (2006) 1.04
Role of CD28 in fatal autoimmune disorder in scurfy mice. Blood (2007) 1.04
Chemotherapy rescues tumor-driven aberrant CD4+ T-cell differentiation and restores an activated polyfunctional helper phenotype. Blood (2010) 1.03
Marginal zone CD169+ macrophages coordinate apoptotic cell-driven cellular recruitment and tolerance. Proc Natl Acad Sci U S A (2014) 1.02
Polyfunctional CD4⁺ T cells are essential for eradicating advanced B-cell lymphoma after chemotherapy. Blood (2012) 1.02
Mouse mesenchymal stem cells suppress antigen-specific TH cell immunity independent of indoleamine 2,3-dioxygenase 1 (IDO1). Stem Cells Dev (2010) 0.97
Indoleamine 2,3-dioxygenase expression promotes renal ischemia-reperfusion injury. Am J Physiol Renal Physiol (2008) 0.97
Dendritic cells have the option to express IDO-mediated suppression or not. Blood (2005) 0.96
Induction and role of indoleamine 2,3 dioxygenase in mouse models of influenza a virus infection. PLoS One (2013) 0.94
CD4(+)CD25(+) regulatory T cells resist a novel form of CD28- and Fas-dependent p53-induced T cell apoptosis. J Immunol (2009) 0.91
Deficiency of indoleamine 2,3-dioxygenase enhances commensal-induced antibody responses and protects against Citrobacter rodentium-induced colitis. Infect Immun (2008) 0.89
Deficient tryptophan catabolism along the kynurenine pathway reveals that the epididymis is in a unique tolerogenic state. J Biol Chem (2010) 0.89
GCN2-dependent metabolic stress is essential for endotoxemic cytokine induction and pathology. Mol Cell Biol (2013) 0.89
T cell regulatory plasmacytoid dendritic cells expressing indoleamine 2,3 dioxygenase. Handb Exp Pharmacol (2009) 0.87
Inhibition of indoleamine 2,3-dioxygenase enhances the T-cell response to influenza virus infection. J Gen Virol (2013) 0.87
Allostimulatory activity of bone marrow-derived plasmacytoid dendritic cells is independent of indoleamine dioxygenase but regulated by inducible costimulator ligand expression. Hum Immunol (2009) 0.85
Altered tryptophan metabolism as a paradigm for good and bad aspects of immune privilege in chronic inflammatory diseases. Front Immunol (2012) 0.85
B7h (ICOS-L) maintains tolerance at the fetomaternal interface. Am J Pathol (2013) 0.84
IFN-gamma-indoleamine-2,3 dioxygenase acts as a major suppressive factor in 4-1BB-mediated immune suppression in vivo. J Leukoc Biol (2009) 0.83
Decreased protein nitration in macrophages that overexpress indoleamine 2, 3-dioxygenase. Cell Mol Biol Lett (2006) 0.83
Macrophages and the regulation of self-reactive T cells. Curr Pharm Des (2003) 0.81
Indoleamine 2,3-dioxygenase 1 (ido1) is involved in the control of mouse caput epididymis immune environment. PLoS One (2013) 0.81
Enrichment of regulatory CD4(+)CD25(+) T cells by inhibition of phospholipase D signaling. Nat Methods (2006) 0.81
Indoleamine 2,3-dioxygenase (IDO) activity during the primary immune response to influenza infection modifies the memory T cell response to influenza challenge. Viral Immunol (2014) 0.80
Constitutively CD40-activated B cells regulate CD8 T cell inflammatory response by IL-10 induction. J Immunol (2013) 0.79
Effect of indoleamine dioxygenase-1 deficiency and kynurenine pathway inhibition on murine cerebral malaria. Int J Parasitol (2008) 0.79
Cytosolic DNA sensing via the stimulator of interferon genes adaptor: Yin and Yang of immune responses to DNA. Eur J Immunol (2014) 0.79
STING, nanoparticles, autoimmune disease and cancer: a novel paradigm for immunotherapy? Expert Rev Clin Immunol (2014) 0.76